Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®) in first-line treatment of metastatic colorectal cancer. The trial will investigate two regimens of FLOX plus cetuximab, in which FLOX is given continuously or intermittently, compared to standard FLOX without cetuximab.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histology and staging disease:
General conditions:
Exclusion criteria
Prior therapy:
Prior or current history:
Concomitant treatments:
Other:
Primary purpose
Allocation
Interventional model
Masking
571 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal